Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Compared the diagnostic performance of 68Ga-MY6349 PET/CT with 68Ga-FAPI PET/CT.
- Who it may be relevant to
- Registry conditions: Tumor, Solid Tumor, Thyroid Cancer. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Trophoblast Cell-Surface Antigen 2 (Trop-2) Targeted PET/CT in Recurrent and Metastatic Thyroid Cancer and Compared With 68Ga-FAPI PET/CT
Overview
In this study, we comprehensively evaluated the clinical utility of Trop2 PET/CT (68Ga-MY6349 PET/CT) imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with those of 68Ga-FAPI PET/CT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET/CT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET/CT, and the impact on clinical management.
Detailed description
Trophoblast cell-surface antigen 2 (Trop2), a transmembrane glycoprotein, is highly expressed in most epithelial cancers but has low expression in most normal tissues. Notably, Trop2 expression is significantly elevated in thyroid cancer, representing an important molecular hallmark of thyroid cancer. Previously, we evaluated the diagnostic performance of 68Ga-MY6349 PET/CT in recurrent and metastatic thyroid cancer and compared it with 18F-FDG PET/CT. The results demonstrated that 68Ga-MY6349 PET/CT was superior to 18F-FDG PET/CT for lesion detection, particularly in patients with PTC and TENIS. In addition, fibroblast activation protein is highly expressed in cancer-associated fibroblasts in thyroid cancer. 68Ga-labeled FAP inhibitor (FAPI) has demonstrated favorable in vivo pharmacokinetics and higher diagnostic accuracy than 18F-FDG in various types of cancers, including thyroid cancer.
In this study, we comprehensively evaluated the clinical utility of 68Ga-MY6349 PET/CT imaging for detecting recurrent and metastatic thyroid cancer, and the results were compared with 68Ga-FAPI PET/CT. The primary objective of this study was to evaluate the patient-based sensitivity of 68Ga-MY6349 PET/CT in detecting recurrent and metastatic thyroid cancer. The secondary objectives included its overall specificity, lesion-based diagnostic performance, comparative tumor uptake relative to 68Ga-FAPI PET/CT, and the impact on clinical management.
Interventions
- Diagnostic test Compared the diagnostic performance of 68Ga-MY6349 PET/CT with 68Ga-FAPI PET/CT
Each subject receives a single intravenous injection of 68Ga-MY6349 and 68Ga-FAPI and undergoes PET/CT imaging within the specified time. For participants who were not radioiodine-refractory or who did not have MTC or ATC, DxWBS was conducted. Each participant received an intramuscular injection of rhTSH on two consecutive days, followed by the oral administration of 131I. DxWBS was performed 2 days after 131I administration
Primary outcome measures
- Diagnostic performance (patient-based) [Time frame: 2 years]
Secondary outcome measures (4)
- Diagnostic performance (patient-based) [Time frame: 2 years]
- Diagnostic performance [Time frame: 2 years]
- SUVmax and TBR [Time frame: 2 years]
- The impact on clinical management [Time frame: 2-4 weeks]
Eligibility criteria
Inclusion criteria
- Adult patients (aged 18 years or older);
- Patients with a history of previously treated thyroid cancer, including DTC and HGFCTC following thyroidectomy with or without 131I therapy, MTC after thyroidectomy, or ATC; either (1) evidence of structural or suspicious lesions on standard of care imaging or (2) biochemical evidence of disease in the absence of structural findings, defined as elevated thyrotropin suppressed thyroglobulin (Tgon ≥1 ng/mL after 131I ablation or ≥5 ng/mL without ablation) with negative anti thyroglobulin antibodies (<20 IU/mL) for DTC and HGFCTC or elevated calcitonin (>10 pg/mL) for MTC;
- Patients who had scheduled both 68Ga-MY6349 and 68Ga-FAPI PET/CT scans;
- Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
- No other anticancer therapy within four weeks prior to PET imaging.
Exclusion criteria
- Pregnant or lactating patients;
- Patients with a second primary tumor;
- The inability or unwillingness of the research participant, parent, or legal representative to provide written informed consent.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian 361000 — Xiamen
Identifiers
NCT: NCT07753499 · XMYY-2026KY052